Ligand Pharmaceuticals | LGND - Заемный капитал





Заемный капитал Изменить Дата
Agenus USD 169.66M 146.06M 2025-12
Amgen USD 51.89B 1.88B 2026-03
Arrowhead Research USD 1.23B 687.3M 2026-03
Baxter International USD 8.62B 852M 2026-03
Bristol-Myers Squibb USD 42.15B 698M 2026-03
Eli Lilly USD 39.37B 1.5B 2026-03
Enanta Pharmaceuticals USD 0 0 2024-12
Enviri Corporation USD 1.56B 26.44M 2026-03
Gilead Sciences USD 20.86B 1.27B 2026-03
GlaxoSmithKline GBP 14.01B 696M 2026-03
Glaxosmithkline GBP 19.82B 203.13M 2025-12
Heron Therapeutics USD 140.64M 975K 2025-12
Insmed USD 542.22M 1.25M 2026-03
Intrexon USD 0 198.67M 2024-06
Ionis Pharmaceuticals USD 1.91B 9M 2026-03
Karyopharm Therapeutics USD 278.22M 278.22M 2025-12
Ligand Pharmaceuticals USD 446.19M 702K 2025-12
MacroGenics USD 70M 256K 2025-12
Merck USD 46.67B 77M 2026-03
Pacira USD 367.66M 4.53M 2026-03
Pfizer USD 60.57B 1.08B 2026-03
Rigel Pharmaceuticals USD 0 0 2024-09
Sangamo BioSciences USD 0 0 2022-06
Veracyte USD 0 0 2025-03